A phase I study of sunitinib plus bevacizumab in advanced solid tumors.
about
Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailabilityDual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkersCombination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomicsDesign of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering CommitteeA phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignanciesMetastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumabTargeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies.Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate.New ways to successfully target tumor vasculature in ovarian cancer.Adrenocortical carcinoma: the management of metastatic disease.Targeting angiogenesis in metastatic breast cancerA phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer.A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for position.Safety profile of new anticancer drugs.Sunitinib for the management of advanced renal cell carcinoma.Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma.VB-111 for cancer.Axitinib in the treatment of metastatic renal cell carcinoma.Posterior reversible encephalopathy syndrome induced by anti-VEGF agents.Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs.Safety and feasibility of targeted agent combinations in solid tumours.The potential of sunitinib as a therapy in ovarian cancer.The emerging quest for the optimal angiostatic combination therapy.Emerging therapeutic approaches in renal cell carcinoma.Sunitinib in kidney cancer: 10 years of experience and development.A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma.Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.The bevacizumab experience in advanced renal cell carcinomaPhase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.Angiogenesis inhibitors in the treatment of prostate cancerCharacterisation of the Morphological, Functional and Molecular Changes in Sunitinib-Resistant Renal Cell Carcinoma Cells
P2860
Q29012696-3299AFE5-346A-4D8D-BC2A-91F37DEA000DQ33415397-1F711013-E111-418A-914C-F5D720EC215EQ33803564-315CEF20-A342-4BAA-98EF-0C83BB04A25AQ34056295-E3AB4786-144D-4F41-AABC-C9AB0DF2AAF2Q34356881-7F4D376F-AF2D-4E2F-8D8E-37E5A95F1D87Q34417804-8C436F5B-9F6E-49F4-A97C-A275CDF3859BQ34627163-B80A9C0A-B8E0-45B8-944F-F45400EEABA5Q34627828-174F12BF-D1A7-456A-925F-9E2C71CFAD6BQ35626845-712A8833-BFE3-44F0-A3FD-F79CA0B9F6FEQ35928220-95542E3F-72A9-4947-A000-CD7A96C8EF40Q36081865-15A4BAE0-7D79-4741-9917-B7A8602556B1Q36182795-10C5E31F-64E5-4BA4-9A02-CF6C0636E0C9Q37166383-FFAA15C0-E91C-479C-BA36-CEBA4A693D32Q37474683-F6F440AA-45D8-4E14-A466-F70602DAEB20Q37602900-BA6531EC-9672-49FF-8A3A-1618790ADF5BQ37696502-795B303F-337F-42B6-B78D-9674AC3F9245Q37705402-37C4267A-B7F9-4CBC-B56C-DA70D4023DC0Q37752357-D11EF002-B053-4DF5-B285-EFFD0E62A92AQ37941051-C2D306CB-56D5-4373-9064-DEBF50C8AD3FQ37951599-3C27EB46-B281-4922-B4B2-28B8B0B31002Q37957052-07FBD959-27D9-4C45-8C49-D1B3530510E1Q37963823-D85621E1-75A6-4F56-ABC3-566C06717A8CQ38077440-7A648894-B9C7-4536-9960-DAFF1895310DQ38144166-0D24778B-ACAA-4E28-BC9F-F7B058DB9858Q38268453-741E2BC7-0ECA-4398-ACE3-D4BADF9929F7Q38587958-2119B2F6-6C28-4B2E-9722-0A740B6AC423Q39038214-ED67A012-8F91-41E5-AE44-151C260A893AQ39532016-29A08AEE-DCD1-47CA-A5D7-02060ABE0634Q41431404-C7A41C34-E4F9-4846-8FE4-182B87CAE910Q41899102-FE0392F1-91F5-4333-B3D8-819A620BEB31Q52670846-E23CDB6E-21D5-4961-A9A7-B48D52792276Q57139434-7DE30FAA-46AE-4F4D-81AA-2AA6386B6A3CQ58790703-CF508827-1FB4-4898-9453-C7A771264D9C
P2860
A phase I study of sunitinib plus bevacizumab in advanced solid tumors.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A phase I study of sunitinib plus bevacizumab in advanced solid tumors.
@ast
A phase I study of sunitinib plus bevacizumab in advanced solid tumors.
@en
type
label
A phase I study of sunitinib plus bevacizumab in advanced solid tumors.
@ast
A phase I study of sunitinib plus bevacizumab in advanced solid tumors.
@en
prefLabel
A phase I study of sunitinib plus bevacizumab in advanced solid tumors.
@ast
A phase I study of sunitinib plus bevacizumab in advanced solid tumors.
@en
P2093
P2860
P1476
A phase I study of sunitinib plus bevacizumab in advanced solid tumors.
@en
P2093
Afshin Dolwati
Allison Tyler
Brian I Rini
Ernest Borden
G Thomas Budd
Helen X Chen
Jorge A Garcia
Joseph Bokar
Kristi Beatty
Matthew M Cooney
P2860
P304
P356
10.1158/1078-0432.CCR-09-0717
P407
P577
2009-09-22T00:00:00Z